TLSA Tiziana Life Sciences Ltd

$TLSA Reasons to hold and not be swayed by the noise; . FDA have launched a dedicated neuroscience initiative. . News has recently come out that the company have completed dosing in the Alzheimer's Phase 2 trial, results Q1 2027. . Positive Phase 2a MS results, with a reduction in Neuroinflammation shown on TSPO-PET scans tying in with the FDA announcement for better use of biomarkers .

$TLSA statistically significant and clinically significant improvements. Very exciting to see these results.

$TLSA Imagine you are Ivor Elrifi. You hold a PhD in biology and a law degree. For 15 years you ran the patent practice at Mintz Levin, then from 2014 you led the global Patent Group at Cooley, one of the world's leading life sciences law firms. Over that career you reviewed thousands of patents covering drugs and how they work. You advised pharma, biotech companies and universities on IP strategy, licensing and M&A, including acquisition transactions involving Novartis, Eli Lilly, Biogen and Astellas. Few people anywhere have seen more drug science from the inside, or know better what big pharma looks for before it buys. Then he chose Tiziana. And what he saw convinced him enough to put around $4M of his own money into the shares, before the key readouts. People with that background don't do that lightly.

$TLSA The par for SPMS is low for Foralumab to succeed - only over 10% of patients have to improve on the EDSS scale to beat Tolebrutinib. Placebo effect is 5%. "HERCULES phase 3 trial of tolebrutinib in non-relapsing secondary progressive MS (nrSPMS), 6-month confirmed disability improvement (CDI) occurred in 8.6% of participants on tolebrutinib versus 4.5% on placebo (hazard ratio 1.88; 95% CI 1.10–3.21)."

$TLSA Do you realize the purpose of the P2a study was to verify the stat sig results at the lower dose? The 100 scale dose was only there to verify that, so it's not a failure. Stop saying it didn't reach Stat Sig, the trial design wasn't intended for that purpose. And the significant drop on the fatigue scale was a positive surprise, that Stat Sig on the second primary endpoint has NEVER BEEN ACHIEVED! NEVER.

$TLSA updated broker notes are useful. Hopefully makes it clearer to people that these results should be celebrated

$TLSA did we just hit the price point where investors say hang on, this is a bit silly now

$TLSA News, finally! Positive, statistically significant results are a great headline for this fine Monday morning.

$TLSA Of course, it’s an exaggeration... The share price will reach completely different levels again... Patience is required... The short sellers have done their homework, but the long investors will get their slice of the pie too... Just one or two more pieces of good data, and we’ll be right back at the forefront... believe it!!!

$TLSA They could still get Accelerated approval with the PET-Scan as surrogate endpoint with obligation to conduct a phase 3 in parallel. The stock price would fly over +200% just like Inovio recently.

$TLSA Trials with an open-label extension (OLE) practically act as an "accidental cheat code" that gives biotech companies a much better idea of how the main blinded trial performed long before the mathematical data is officially unblinded. Even though the historical 12-week data is strictly locked away in a computer system until the very end, watching the exact same patients transition into the OLE drops clear signals. This phenomenon explains why biotech executives often project massive confidence, and why insiders like Ivor Elrifi buy millions of dollars of stock right as patient visits wrap up. They aren't looking at the final unblinded spreadsheet yet, but they can read the obvious clues playing out across the clinics.

$TLSA Follow the money. Since December, CEO Ivor Elrifi has put around $4M of his own cash into Tiziana shares, months before the key readouts. If he expected a heavily dilutive raise at depressed prices, buying now would make little sense: he would simply be watching his own stake get diluted along with everyone else's. Insiders buy for one reason, and it usually isn't because they expect things to get worse. With INFORM-MS reporting this month, Alzheimer's topline due in Q1 2027 and the platform widening into ALS and MSA, it looks like a management team positioning for what comes next.

$TLSA POSITIVE trial - both clinically and statistically significant. Can't ask for any more. Now let's all watch the high frequency traders and the shorts play their game and then try and exit over the next few days. I'm BUYING more.

$TLSA I think the data is good enough for atleast to try to get Accelerated approval. Patient numbers with EA are sufficient.

$TLSA To our knowledge, the first nasally administered monoclonal antibody to meet a primary endpoint in a randomised, placebo-controlled trial?

$TLSA Perhaps it’s just because I’m an optimistic person, but I’d like you to consider a few points: - Elrifi stated that several companies have requested the preliminary data before it is officially released. - Tiziana, while always scrupulous about disclosing information, hasn’t said anything regarding the delays; instead, they simply announced that the commercial team traveled to the MS Toronto meeting—why mention this? And why go to the expense of bringing the entire team if the data were negative? - Tiziana could have presented the preliminary data at the MS Toronto meeting—why didn’t they? - If the data were negative, would there be any advantage to waiting before announcing it? I could certainly be wrong, but in my view, they already have the preliminary—or perhaps even the final—data, and they are currently finalizing an agreement before making it public.

$TLSA most biotechs in the red today but not Tiziana. That’s because of the imminent phase 2a SPMS data readout, along with the multiple other catalysts coming up. Combined with the high likelihood of a partnership or buyout to follow🔥 Still time to load up! $XBI

$TLSA 🏥 Tiziana Life Sciences reported positive Phase 2a INFORM-MS topline results showing the trial met its primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168), favorable safety at both doses, and clinically meaningful fatigue improvements in both dose arms after 12 weeks. Actionable market event

$TLSA looks to be forming an inverse head and shoulders on daily with a re-test of broad inverse head and shoulders on monthly. bullish tlsa.

$TLSA If I buy a stock and it drops, I can hold onto it and wait, and it costs me nothing. If I am short and a stock rises while I wait, I pay interest and could lose more than my total capital.